VCEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VCEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Vericel's revenue for the three months ended in Dec. 2024 was $75.4 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $237.2 Mil. Vericel's Revenue per Share for the three months ended in Dec. 2024 was $1.24. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $4.57.
During the past 12 months, the average Revenue per Share Growth Rate of Vericel was 10.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 10.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Vericel's highest 3-Year average Revenue per Share Growth Rate was 632.20% per year. The lowest was -76.00% per year. And the median was -10.35% per year.
The historical data trend for Vericel's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
124.18 | 156.18 | 164.37 | 197.52 | 237.22 |
Vericel Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
65.00 | 51.28 | 52.66 | 57.91 | 75.38 |
For the Biotechnology subindustry, Vericel's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vericel's Revenue distribution charts can be found below:
* The bar in red indicates where Vericel's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $237.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (NAS:VCEL) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Vericel's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin F Mclaughlin | director | C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
Jonathan Siegal | officer: Principal Accounting Officer | C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Zerbe Robert L Md | director | |
Paul K Wotton | director | C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341 |
Jonathan Mark Hopper | officer: Chief Medical Officer | 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Dominick Colangelo | director, officer: President and CEO | 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Sean C. Flynn | officer: SVP, General Counsel | C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139 |
Mara Joseph Anthony Jr | officer: Chief Financial Officer | C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Michael Halpin | officer: Chief Operating Officer | C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139 |
Lisa Wright | director | C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Sandra Pennell | officer: VP and Corporate Controller | C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139 |
Gerard J Michel | officer: CFO & VP , Corp. Development | 420 CHIPETA WAY, SALT LAKE CITY UT 84108 |
Daniel Orlando | officer: Chief Operating Officer | P.O. BOX 376, ANN ARBOR MI 48105 |
Alan L Rubino | director | PO BOX 376, LOBBY L., ANN ARBOR MI 48105 |
From GuruFocus
By Marketwired • 01-14-2025
By GuruFocus News • 02-13-2025
By Marketwired • 10-24-2024
By Marketwired • 08-07-2024
By GuruFocus News • 11-06-2024
By GuruFocus News • 11-08-2024
By Marketwired • 05-22-2024
By Marketwired • 08-29-2024
By GuruFocus News • 02-15-2025
By Marketwired • 08-26-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.